Date: Tuesday 24 Apr 2012
LONDON (ShareCast) - Vectura, the pharma company specialising in treatments for respiratory diseases, says a trial of one of its development drugs has shown better results than the main competitor.
The not-catchily titled QVA149 is a treatment delivered through an inhaler, mainly targeted at chronic obstructive pulmonary disease - a condition often seen in smokers, or people working in a polluted environment, which can cause debilitating bouts of breathlessness.
The latest study results show a once daily dose of QVA149 gives patients “superior” lung function to the twice daily treatment Seretide.
The drug will now progress to phase III trials in the US, managed by its partner in the project, pharma giant, Novartis.
Vectura shares had gained 4.35% by 10:12.
or share it with one of these popular networks:
|% Change||1.15 %|
|52 Week High||96.75|
|52 Week Low||64.00|
|No dividends found|
|Time||Volume / Share Price|
|16:35||6,702 @ 88.00p|
|16:26||31 @ 88.00p|
|16:21||278 @ 87.75p|
|16:21||96 @ 87.75p|
|16:19||800 @ 87.75p|
You are here: research